
Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Saccharomyces boulardii CNCM I-745 is a probiotic yeast that produces bioactive compounds like polyamines and proteases to restore gut microbiota balance. It prevents diarrhea by inhibiting pathogenic bacteria adhesion and strengthening intestinal barrier function through enhanced tight junction proteins.

Reported Benefits (Provisional)
Origin & History

Saccharomyces boulardii CNCM I-745 is a probiotic yeast isolated from tropical fruits. It is produced through fermentation and is commonly used in dietary supplements.
Research Narrative (Provisional)
Saccharomyces boulardii CNCM I-745 has been extensively studied, with numerous RCTs demonstrating its efficacy in preventing and treating diarrhea. Meta-analyses confirm its benefits in various gastrointestinal conditions.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Contains live probiotic yeast cultures. - Produces bioactive compounds that support gut health. - Rich in enzymes that aid digestion.
Reported Mechanism (Provisional)
Saccharomyces boulardii produces proteases that degrade bacterial toxins and releases polyamines that enhance intestinal epithelial cell proliferation. It competitively inhibits pathogenic bacteria adhesion to intestinal mucosa by binding to common receptor sites. The yeast stimulates secretory IgA production and increases expression of tight junction proteins like claudin-1 and occludin to strengthen intestinal barrier integrity.
Clinical Narrative (Provisional)
Multiple randomized controlled trials with 50-400 participants demonstrate Saccharomyces boulardii CNCM I-745 reduces antibiotic-associated diarrhea incidence by 57-70% when taken at 250-500mg twice daily. Meta-analyses of 31 studies show significant efficacy in preventing Clostridium difficile-associated diarrhea with NNT of 12.5. Studies in traveler's diarrhea show 40-50% reduction in symptom duration and severity. Evidence quality is considered moderate to high for diarrhea prevention, with most studies showing consistent beneficial outcomes across diverse populations.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.







